When lifestyle changes alone arent enough, GLP-1 medications can help fill the gap
Based on the research and clinical trials, here are the disease states and associated risk reductions with GLP-1 medications: Cardiovascular Disease: Major adverse cardiovascular events (MACE): 20-26% reduction Heart attack: ~20% reduction Stroke: ~20% reduction Cardiovascular death: ~15-20% reduction Heart Failure: Heart failure with preserved ejection fraction (HFpEF): Improved symptoms, exercise tolerance, and body composition Heart failure hospitalizations: Reduced (specific percentages vary by study) Kidney Disease: Progression to end-stage renal disease: 20-30% reduction Decline in eGFR: Slowed progression Type 2 Diabetes: Progression from prediabetes to diabetes: Reduced risk (specific percentage varies) Liver Disease: NAFLD/NASH improvement: Reduced liver fat and inflammation Liver enzyme normalization: Significant improvement in ALT/AST Obesity-Related Complications: Body weight reduction: 10-15% (semaglutide), 15-22% (tirzepatide) Visceral fat reduction: Substantial decrease Metabolic Syndrome Components: Blood pressure: 5-10 mmHg reduction in systolic BP Triglycerides: 20-30% reduction Insulin resistance: Significant improvement Cancer: (emerging data) Overall cancer risk: Potential reduction (10-20% suggested in some observational studies) Specific cancers linked to obesity/metabolic dysfunction: Reduced risk observed Neurodegeneration: (preliminary data) Alzheimers disease progression: Some trials are ongoing, but recent data have been unpromising
Key symptoms Loose, watery stools Increased frequency of bowel movements Urgency to defecate Abdominal cramping or pain Possible nausea Bloating or gas Risk of dehydration and electrolyte imbalances if severe How common is diarrhoea with GLP-1 treatments
Last Updated on April 30, 2026 by Patrick A
In Conclusion Until there is more evidence-based research on the impact of GLC-1 receptor agonists on anesthesia, specifically conscious sedation, DOCS Education recommends a medical consult with the patients PCP or endocrinologist, and absent the strong recommendation to the contrary from their prescribing physician, have the patient withhold their weekly injectable GLP-1 receptor antagonist one week before sedation, and their daily GLP-1 receptor agonist on the day of the sedation appointment, and be NPO 6 hours before the appointment as usual
